CHICAGO -- Teclistamab (Tecvayli) monotherapy significantly improved survival compared with standard therapies in patients with multiple myeloma who had received up to three previous lines of therapy, the phase III MajesTEC-9 trial showed.
The estimated 18-month progression-free survival (PFS) rate was 69.8% with teclistamab compared with 26.9% with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) or carfilzomib (Kyprolis) and dexamethasone (Kd; HR 0.29, 95% CI 0.23-0.38, P<0.001), reported Cyrille Touzeau, MD, PhD, of the University Hospital of Nantes in France, and colleagues.
The estimated 18-month overall survival rates were 79.2% versus 68.6%, respectively (HR 0.60, 95% CI 0.43-0.83, P=0.002).
The findings were presented at the American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine.
Along with results from MajesTEC-3, in which treatment with teclistamab and subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) significantly improved PFS in patients who had received up to three previous lines of therapy, these results "support the use of teclistamab-based, glucocorticoid-sparing regimens as second-line and later treatment options for multiple myeloma across a range of practice settings," Touzeau and colleagues wrote.
